Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias: Shedding new light on an old enzyme

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Standard

Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias : Shedding new light on an old enzyme. / van Dijk, Myrthe J.; de Wilde, Jonathan R.A.; Bartels, Marije; Kuo, Kevin H.M.; Glenthøj, Andreas; Rab, Minke A.E.; van Beers, Eduard J.; van Wijk, Richard.

I: Blood Reviews, Bind 61, 101103, 2023.

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Harvard

van Dijk, MJ, de Wilde, JRA, Bartels, M, Kuo, KHM, Glenthøj, A, Rab, MAE, van Beers, EJ & van Wijk, R 2023, 'Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias: Shedding new light on an old enzyme', Blood Reviews, bind 61, 101103. https://doi.org/10.1016/j.blre.2023.101103

APA

van Dijk, M. J., de Wilde, J. R. A., Bartels, M., Kuo, K. H. M., Glenthøj, A., Rab, M. A. E., van Beers, E. J., & van Wijk, R. (2023). Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias: Shedding new light on an old enzyme. Blood Reviews, 61, [101103]. https://doi.org/10.1016/j.blre.2023.101103

Vancouver

van Dijk MJ, de Wilde JRA, Bartels M, Kuo KHM, Glenthøj A, Rab MAE o.a. Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias: Shedding new light on an old enzyme. Blood Reviews. 2023;61. 101103. https://doi.org/10.1016/j.blre.2023.101103

Author

van Dijk, Myrthe J. ; de Wilde, Jonathan R.A. ; Bartels, Marije ; Kuo, Kevin H.M. ; Glenthøj, Andreas ; Rab, Minke A.E. ; van Beers, Eduard J. ; van Wijk, Richard. / Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias : Shedding new light on an old enzyme. I: Blood Reviews. 2023 ; Bind 61.

Bibtex

@article{9589b0b901854e18b1328900d9ffea5f,
title = "Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias: Shedding new light on an old enzyme",
abstract = "Novel developments in therapies for various hereditary hemolytic anemias reflect the pivotal role of pyruvate kinase (PK), a key enzyme of glycolysis, in red blood cell (RBC) health. Without PK catalyzing one of the final steps of the Embden-Meyerhof pathway, there is no net yield of adenosine triphosphate (ATP) during glycolysis, the sole source of energy production required for proper RBC function and survival. In hereditary hemolytic anemias, RBC health is compromised and therefore lifespan is shortened. Although our knowledge on glycolysis in general and PK function in particular is solid, recent advances in genetic, molecular, biochemical, and metabolic aspects of hereditary anemias have improved our understanding of these diseases. These advances provide a rationale for targeting PK as therapeutic option in hereditary hemolytic anemias other than PK deficiency. This review summarizes the knowledge, rationale, (pre)clinical trials, and future advances of PK activators for this important group of rare diseases.",
keywords = "Glycolysis, Hemolytic anemia, Pyruvate kinase, Treatment",
author = "{van Dijk}, {Myrthe J.} and {de Wilde}, {Jonathan R.A.} and Marije Bartels and Kuo, {Kevin H.M.} and Andreas Glenth{\o}j and Rab, {Minke A.E.} and {van Beers}, {Eduard J.} and {van Wijk}, Richard",
note = "Corrigendum: https://doi.org/10.1016/j.blre.2023.101160 Publisher Copyright: {\textcopyright} 2023",
year = "2023",
doi = "10.1016/j.blre.2023.101103",
language = "English",
volume = "61",
journal = "Blood Reviews",
issn = "0268-960X",
publisher = "Churchill Livingstone",

}

RIS

TY - JOUR

T1 - Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias

T2 - Shedding new light on an old enzyme

AU - van Dijk, Myrthe J.

AU - de Wilde, Jonathan R.A.

AU - Bartels, Marije

AU - Kuo, Kevin H.M.

AU - Glenthøj, Andreas

AU - Rab, Minke A.E.

AU - van Beers, Eduard J.

AU - van Wijk, Richard

N1 - Corrigendum: https://doi.org/10.1016/j.blre.2023.101160 Publisher Copyright: © 2023

PY - 2023

Y1 - 2023

N2 - Novel developments in therapies for various hereditary hemolytic anemias reflect the pivotal role of pyruvate kinase (PK), a key enzyme of glycolysis, in red blood cell (RBC) health. Without PK catalyzing one of the final steps of the Embden-Meyerhof pathway, there is no net yield of adenosine triphosphate (ATP) during glycolysis, the sole source of energy production required for proper RBC function and survival. In hereditary hemolytic anemias, RBC health is compromised and therefore lifespan is shortened. Although our knowledge on glycolysis in general and PK function in particular is solid, recent advances in genetic, molecular, biochemical, and metabolic aspects of hereditary anemias have improved our understanding of these diseases. These advances provide a rationale for targeting PK as therapeutic option in hereditary hemolytic anemias other than PK deficiency. This review summarizes the knowledge, rationale, (pre)clinical trials, and future advances of PK activators for this important group of rare diseases.

AB - Novel developments in therapies for various hereditary hemolytic anemias reflect the pivotal role of pyruvate kinase (PK), a key enzyme of glycolysis, in red blood cell (RBC) health. Without PK catalyzing one of the final steps of the Embden-Meyerhof pathway, there is no net yield of adenosine triphosphate (ATP) during glycolysis, the sole source of energy production required for proper RBC function and survival. In hereditary hemolytic anemias, RBC health is compromised and therefore lifespan is shortened. Although our knowledge on glycolysis in general and PK function in particular is solid, recent advances in genetic, molecular, biochemical, and metabolic aspects of hereditary anemias have improved our understanding of these diseases. These advances provide a rationale for targeting PK as therapeutic option in hereditary hemolytic anemias other than PK deficiency. This review summarizes the knowledge, rationale, (pre)clinical trials, and future advances of PK activators for this important group of rare diseases.

KW - Glycolysis

KW - Hemolytic anemia

KW - Pyruvate kinase

KW - Treatment

U2 - 10.1016/j.blre.2023.101103

DO - 10.1016/j.blre.2023.101103

M3 - Review

C2 - 37353463

AN - SCOPUS:85166909129

VL - 61

JO - Blood Reviews

JF - Blood Reviews

SN - 0268-960X

M1 - 101103

ER -

ID: 388025194